Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Veru save search
Veru, Immunome Tout Positive Data for COVID-19 Therapeutics
Published: 2022-07-06 (Crawled : 17:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
IMNM | $15.5 -9.78% -10.84% 2.1M
|
Health Technology
|
| O: 2.63%
H: 12.54%
C: 9.69%
covid-19 therapeutics positive
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 8.28%
H: 2.44%
C: -19.07%
covid-19 fda sabizabulin granted authorization positive phase 3 emergency use authorization
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -4.25%
H: 3.62%
C: -1.17%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: 0.04%
prostate cancer phase 1 positive cancer phase 1b sabizabulin phase 2b
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.92%
H: 5.56%
C: 1.82%
phase 2 positive therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
Published: 2021-05-05 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.23%
H: 6.88%
C: -15.97%
presentation phase 2 positive cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2021-02-08 (Crawled : 13:26) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 17.94%
H: 22.18%
C: 8.33%
covid positive results respiratory phase 2 risk syndros
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 4.43%
H: 1.19%
C: -4.4%
positive endocrine cancer breast cancer hormone therapy metastatic breast cancer
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 55.31%
H: 9.73%
C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.